Filing Details

Accession Number:
0001209191-20-001233
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-03 17:21:46
Reporting Period:
2019-12-31
Accepted Time:
2020-01-03 17:21:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178879 Amicus Therapeutics Inc. FOLD Pharmaceutical Preparations (2834) 200422823
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1601896 Jay Barth C/O Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury NJ 08512
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-12-31 10,826 $9.74 137,674 No 4 F Direct
Common Stock Acquisiton 2020-01-02 61,601 $0.00 199,275 No 4 A Direct
Common Stock Disposition 2020-01-02 9,753 $9.55 189,522 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Acquisiton 2020-01-02 96,818 $0.00 96,818 $9.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
96,818 2030-01-02 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 20 Indirect By Daughter
Footnotes
  1. Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
  2. The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2021.
  3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  4. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.50 to $9.61 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter.